IBM, P&G, GameStop, Crispr, AGNC: Insider Moves Exposed

Insiders have been trading these 5 stocks: ((IBM)), ((PG)), ((GME)), ((CRSP)) and ((AGNC)). Here is a breakdown of their recent trades and their value.

Director David Farr’s latest move at International Business Machines has drawn fresh attention to the tech stalwart, as he purchased 1,000 shares of IBM stock in a transaction worth $304,000. Insider buying of this size is often read as a vote of confidence in the company’s future, suggesting that Farr sees value in IBM’s strategy and outlook. For existing and potential shareholders, the $304,000 commitment underscores that leadership believes the current share price may understate the company’s long-term potential in areas like hybrid cloud and AI.

At Procter & Gamble, Chief Brand Officer Marc Pritchard has gone the other direction, selling 95,903 shares of the consumer products giant in a transaction totaling $14,494,779. A sale of nearly $14.5 million in stock is substantial, and investors may wonder whether this reflects portfolio diversification, personal financial planning, or a view on P&G’s valuation after a strong run. While one transaction doesn’t rewrite the company’s fundamentals, the sale of 95,903 shares is a notable data point for those tracking insider sentiment at Procter & Gamble.

GameStop, long a lightning rod for retail investor enthusiasm, saw a fresh insider vote of confidence as Director Lawrence Cheng purchased 5,000 shares worth $114,350. In a stock known for volatility and meme-fueled rallies, an insider buying $114,350 of shares can stand out as a more grounded, fundamentals-driven signal. For followers of GameStop’s turnaround story—from brick-and-mortar retailer to a more digital-focused model—the acquisition of 5,000 shares by a director may be interpreted as belief in the next phase of the company’s evolution.

Crispr Therapeutics AG, a key player in gene-editing biotechnology, drew attention when CMO Naimish Patel bought 1,508 shares, a purchase valued at $49,703. In a sector where breakthrough therapies and regulatory milestones can dramatically impact valuations, insider buying is often closely watched. Patel’s $49,703 commitment to 1,508 shares may signal confidence in the company’s clinical pipeline and upcoming catalysts, reinforcing the idea that leadership sees considerable upside in Crispr Therapeutics’ long-term prospects.

AGNC Investment has been the site of significant insider selling activity, with three senior executives unloading large blocks of shares. EVP and CFO Bernice Bell sold 25,000 shares for $303,500, while SVP, CCO and Secretary Kenneth L. Pollack sold 50,000 shares for $605,500. The largest move came from Director, CEO, President and CIO Gary Kain, who sold a massive 700,000 shares, generating proceeds of $8,330,000. Taken together, these sales—totaling 775,000 shares and more than $9.2 million in value—are substantial and may prompt investors in AGNC Investment to closely consider how these insider actions fit alongside the company’s dividend strategy, interest-rate exposure, and broader market conditions.